RegentAtlantic Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

RegentAtlantic Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$4.3M	Buy	14,836 +7,964	+116%	+$2.29M	0.13%	117
2022 Q2	$1.94M	Buy	6,872 +724	+12%	+$194K	0.06%	215
2022 Q1	$1.6M	Buy	6,148 +1,078	+21%	+$256K	0.05%	249
2021 Q4	$1.11M	Buy	5,070 +1,096	+28%	+$213K	0.03%	309
2021 Q3	$721K	Buy	3,974 +136	+4%	+$26.6K	0.02%	361
2021 Q2	$774K	Buy	3,838 +138	+4%	+$28.9K	0.02%	333
2021 Q1	$795K	Buy	3,700 +1,371	+59%	+$301K	0.03%	309
2020 Q4	$550K	Sell	2,329 -33	-1%	-$7.57K	0.02%	325
2020 Q3	$643K	Buy	2,362 +1,040	+79%	+$287K	0.03%	289
2020 Q2	$384K	Buy	+1,322	New	+$358K	0.02%	340
2015 Q1	–	Sell	-115	Closed	-$13.7K	–	942
2014 Q4	$13.7K	Buy	+115	New	+$13K	﹤0.01%	839

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RegentAtlantic Capital's VRTX Position: Q3 2022 in Review

RegentAtlantic Capital increased its Vertex Pharmaceuticals (VRTX) stake by 116% in Q3 2022, buying an estimated $2.29M and bringing the position to 14,836 shares worth $4.3M. The position accounts for 0.13% of the portfolio, ranked #117.

RegentAtlantic Capital first reported a position in VRTX in Q4 2014 and has held it in 11 quarters since. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

RegentAtlantic Capital held 14,836 shares of Vertex Pharmaceuticals worth $4.3M as of Q3 2022.
RegentAtlantic Capital bought 7,964 Vertex Pharmaceuticals shares in Q3 2022, an estimated $2.29M.
Vertex Pharmaceuticals made up 0.13% of RegentAtlantic Capital's portfolio in Q3 2022, its #117 holding.
RegentAtlantic Capital first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 11 quarters since.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.